Seeking to change lives with next generation peptide therapeutics

FY 2023 Financial Results

February 27, 2024
2:00pm CET (8:00am ET)
Read more
Event
Presentation

Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% ...

Zealand Pharma’s Obesity R&D Event

Phase 3 clinical trials to investigate survodutide for people living with obesity and overweight…

Our research

Applying our peptide platform to specialty disease areas to invent novel therapies.
Read more

Clinical pipeline

Advancing development programs in rare diseases and obesity. See our pipeline

About Zealand

Get a brief overview on Zealand and learn more about our company. Read more

Investors

Information for analysts, investors, and shareholders.
Read more